Daily Mail India
People Inbox @ Single Platform

Coronavirus vaccine update: Moderna covid-19 generates immune response in older adults



Oct. 2, 2020, 10:37 a.m.

New Delhi: Everyone around the globe is dedicatedly working towards developing a vaccine for novel coronavirus which has claimed hundreds of thousand lives worldwide. Many candidates involved in developing the vaccine have assured to launch the vaccine as early as 2021. 

India is also working towards developing its indigenous vaccine for the virus. Talking about the same, Union Health Minister Harsh Vardhan said that three firms across the country are currently focusing on developing a successful covid-19 vaccine. 

The government has also launched a website — vaccine.icmr.org.in — to provide all important info related to the development of vaccine in the country. 

The United States, which remains the worst-hit country by the pandemic, is also involved in manufacturing the covid-19 vaccine. Trump administration has even claimed to make a vaccine candidate available for public use before November election. However, the firms working on the vaccines as well as health professionals slammed Trump’s claim. 

Meanwhile, Moderna, which is one of the three vaccine candidates to conduct late stage trials in the US, has showed some positive results. According to a report published in New England Journal of Medicine, the vaccine was able to generate immune response among the volunteers successfully. 

The study noted that the experimental vaccine, mRNA-1273, was well-tolerated by the older trial participants, who were over 55 years of age.

It has been proven that older adults are more vulnerable to covid-19 complications and should be the one of the first groups to be vaccinated. 

The biotech firm, however, emhapsized that it won’t seek an emergency autorization for its coronavirus vaccine before November 25. 

 “November 25 is the time we will have enough safety data to be able to put into an EUA file that we would send to the FDA (Food and Drug Administration) – assuming that the safety data is good, i.e. a vaccine is deemed to be safe,” Moderna CEO told Financial Times. 

Pfizer – another vaccine candidate conducting late stage trials – have said that the company may have a clear answer by the end of October whether their shot works.

Meanwhile, Russia’s second vaccine candidate passed early clinical trials on Thursday. Russia’s Vektor – a top-secret state virology research centre in Siberia – said early-stage trials were successful for its own experimental vaccine, named EpiVacCorona.



Source link